

Integrin beta 1 / CD29 antibody [BV7]

Cat. No. GTX54427

Host	Mouse
Clonality	Monoclonal
Isotype	IgG1
Applications	WB, FCM, IP, ELISA, Neutralizing /Inhibition
Reactivity	Human

Package
50 µg

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	Assay dependent
FCM	Assay dependent
IP	Assay dependent
ELISA	Assay dependent
Neutralizing /Inhibition	Assay dependent

Note : Cells were fixed in 4% paraformaldehyde before staining.

Antibody BV7 functions as an inhibiting antibody. The antibody was functionally tested by adhesion assay, chemotaxis, patch clamp analysis and neurotoxicity induced apoptosis.

Not tested in other applications.

Calculated MW 88 kDa. ([Note](#))

Product Note

This antibody stains the extracellular domain of beta-1 integrin. The monoclonal antibody BV7 does not recognize $\alpha 5\beta 1$ complex and not the cytoplasmic part of the $\beta 1$ -subunit. Monoclonal antibody BV7 is active on HT-29 colon carcinoma cells and on HCCP-2998 tumor cells. BV7 binds to several other tumor cells (MG3 osteosarcoma, A375 melanoma, MHCC-1410 and Lovo colon carcinoma) but does not affect adhesion to endothelial cells.

Properties

Form	Liquid
Buffer	Filter-sterilized PBS, 0.1% BSA
Preservative	No preservatives
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C.
Concentration	100 µg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	Human umbilical vein EC



For full product information, images and publications, please visit our [website](#).

Purification

Purified IgG1

Conjugation

Unconjugated

Note

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).